{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:34:19Z","timestamp":1786365259466,"version":"build-2736575974"},"reference-count":43,"publisher":"The Pediatric Pharmacy Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>Limited guidance on opioid use exists in the pediatric population, causing medication safety concerns for pain management in children and adolescents. Opioid misuse and opioid use disorder continue to greatly affect adolescents and young adults in the United States, furthering the apprehension of their use. The Pediatric Pharmacy Association (PPA) recommends that pharmacists contribute their knowledge to pain management in children, including discussing the appropriate use of non-opioid alternatives for pain and when to recommend co-prescribing naloxone. The PPA also supports the review of electronic prescription drug monitoring programs before opioid prescribing and dispensing by both prescribers and pharmacists, respectively. Education by pharmacists of children and their families regarding proper administration, storage, and disposal, as well as the awareness of opioid misuse and use disorder among adolescents and young adults, is key to prevention. If opioid use disorder is diagnosed, PPA encourages improved access among adolescents to evidence-based medications, including methadone, buprenorphine, and naltrexone. Furthermore, pharmacists should assist with, or in some settings perform, screening and referral to evidence-based treatments.<\/jats:p>","DOI":"10.5863\/jppt-25-00157","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:26:28Z","timestamp":1786364788000},"page":"560-565","source":"Crossref","is-referenced-by-count":0,"title":["Opioid Use in Children"],"prefix":"10.5863","volume":"31","author":[{"given":"Kelly L.","family":"Matson","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice (KLM), University of Rhode Island College of Pharmacy, Kingston, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter N.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Clinical and Administrative Sciences (PNJ), University of Oklahoma College of Pharmacy, Oklahoma City, OK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan R.","family":"Horton","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice (ERH), Massachusetts College of Pharmacy and Health Sciences University, Worcester, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"key":"JPPT-25-00157-b01","series-title":"MMWR Recomm Rep","first-page":"1","article-title":"CDC Guideline for prescribing opioids for chronic pain - United States, 2022","volume":"71","author":"Dowell","year":"2022","unstructured":"Dowell D, Ragan KR, Jones CM, et al. CDC Guideline for prescribing opioids for chronic pain - United States, 2022. MMWR Recomm Rep  2022;71:1\u201395."},{"issue":"No. RR-1","key":"JPPT-25-00157-b02","series-title":"MMWR Recomm Rep","first-page":"1","article-title":"CDC Guideline for prescribing opioids for chronic pain \u2014 United States, 2016","volume":"65","author":"Dowell","year":"2016","unstructured":"Dowell D, Haegerich TM, Chou R. CDC Guideline for prescribing opioids for chronic pain \u2014 United States, 2016. MMWR Recomm Rep  2016;65(No. RR-1):1\u201349."},{"key":"JPPT-25-00157-b03","series-title":"Blood Adv","first-page":"2656","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain","volume":"4","author":"Brandow","year":"2020","unstructured":"Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv  2020; 4:2656\u2013701."},{"issue":"1","key":"JPPT-25-00157-b04","series-title":"JAMA Surg","first-page":"76","article-title":"Guidelines for opioid prescribing in children and adolescents after surgery: an expert panel opinion","volume":"156","author":"Kelley-Quon","year":"2021","unstructured":"Kelley-Quon LI, Kirkpatrick MG, Ricca RL, et al. Guidelines for opioid prescribing in children and adolescents after surgery: an expert panel opinion. JAMA Surg. 2021; 156(1):76\u201390."},{"key":"JPPT-25-00157-b05","series-title":"Narcotics in the medicine cabinet: provider talk is key to lower risk. May","article-title":"National Poll on Children\u2019s Health","year":"2016","unstructured":"CS Mott Children\u2019s Hospital. National Poll on Children\u2019s Health. Narcotics in the medicine cabinet: provider talk is key to lower risk. May  2016. Accessed September 29, 2025. https:\/\/mottpoll.org\/sites\/default\/files\/documents\/051616_painmeds.pdf."},{"issue":"4","key":"JPPT-25-00157-b06","series-title":"J Patient Saf","first-page":"299","article-title":"Implementation of guidelines limiting postoperative opioid prescribing at a children\u2019s hospital","volume":"20","author":"Stephenson","year":"2024","unstructured":"Stephenson KJ, Krinock DJ, Vasquez IL, et al. Implementation of guidelines limiting postoperative opioid prescribing at a children\u2019s hospital. J Patient Saf.  2024;20(4):299\u2013305."},{"issue":"1","key":"JPPT-25-00157-b07","series-title":"J Pediatr Orthop","first-page":"e83","article-title":"Tiered guidelines in a pediatric orthopaedic practice reduce opioids prescribed at discharge","volume":"42","author":"Baker","year":"2022","unstructured":"Baker CE, Larson AN, Ubl DS, et al. Tiered guidelines in a pediatric orthopaedic practice reduce opioids prescribed at discharge. J Pediatr Orthop. 2022;42(1):e83\u2013e90."},{"key":"JPPT-25-00157-b08","series-title":"Pediatr Crit Care Med","first-page":"74","article-title":"2022 Society of Critical Care Medicine clinical practice guidelines on prevention and management of pain, agitation, neuromuscular blockade, and delirium in critically ill pediatric patients with consideration of the ICU environment and early mobility","volume":"23","author":"Smith","year":"2022","unstructured":"Smith HA, Besunder JB, Betters KA, et al. 2022 Society of Critical Care Medicine clinical practice guidelines on prevention and management of pain, agitation, neuromuscular blockade, and delirium in critically ill pediatric patients with consideration of the ICU environment and early mobility. Pediatr Crit Care Med. 2022;23:74\u2013110."},{"issue":"5","key":"JPPT-25-00157-b09","series-title":"Pediatrics","first-page":"e2024068752","article-title":"Opioid prescribing for acute pain management in children and adolescents in outpatient settings: clinical practice guidelines","volume":"154","author":"Hadland","year":"2024","unstructured":"Hadland SE, Agarwal R, Raman SR, et al. American Academy of Pediatrics. Opioid prescribing for acute pain management in children and adolescents in outpatient settings: clinical practice guidelines. Pediatrics. 2024;154(5):e2024068752."},{"issue":"3","key":"JPPT-25-00157-b10","series-title":"Pediatrics","first-page":"e2021051539","article-title":"Opioid prescribing to US children and young adults in 2019","volume":"148","author":"Chua","year":"2021","unstructured":"Chua KP, Brummett CM, Conti RM, Bohnert AS. Opioid prescribing to US children and young adults in 2019. Pediatrics. 2021;148(3):e2021051539."},{"issue":"5","key":"JPPT-25-00157-b11","series-title":"Pediatrics","first-page":"e1169\u20131177","article-title":"Prescription opioids in adolescence and future opioid misuse","volume":"136","author":"Miech","year":"2015","unstructured":"Miech R, Johnston L, O\u2019Malley PM, et al. Prescription opioids in adolescence and future opioid misuse. Pediatrics. 2015;136(5):e1169\u20131177."},{"key":"JPPT-25-00157-b12","article-title":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2023 National Survey on Drug Use and Health (HHS Publication No. PEP24-07-021, NSDUH Series H-59)","year":"2024","unstructured":"Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2023 National Survey on Drug Use and Health (HHS Publication No. PEP24-07-021, NSDUH Series H-59). 2024. Accessed September 29, 2025. https:\/\/www.samhsa.gov\/data\/report\/2023-nsduh-annual-national-report"},{"key":"JPPT-25-00157-b13","series-title":"N Engl J Med","first-page":"97","article-title":"The overdose crisis among U.S. adolescents","volume":"390","author":"Friedman","year":"2024","unstructured":"Friedman J, Hadland SE. The overdose crisis among U.S. adolescents. N Engl J Med. 2024;390:97\u2013100."},{"issue":"9","key":"JPPT-25-00157-b14","series-title":"J Am Dent Assoc","first-page":"814","article-title":"Evidence-based clinical practice guideline for the pharmacologic management of acute dental pain in children: a report from the American Dental Association Science and Research Institute, the University of Pittsburgh School of Dental Medicine, and the Center for Integrative Global Oral Health at the University of Pennsylvania","volume":"154","author":"Carrasco-Labra","year":"2023","unstructured":"Carrasco-Labra A, Polk DE, Urquhart O, et al. Evidence-based clinical practice guideline for the pharmacologic management of acute dental pain in children: a report from the American Dental Association Science and Research Institute, the University of Pittsburgh School of Dental Medicine, and the Center for Integrative Global Oral Health at the University of Pennsylvania. J Am Dent Assoc. 2023;154(9):814\u2013825.e2."},{"issue":"5","key":"JPPT-25-00157-b15","series-title":"Pediatrics","first-page":"e1343","article-title":"More codeine fatalities after tonsillectomy in North American children","volume":"129","author":"Kelly","year":"2012","unstructured":"Kelly LE, Rieder M, van den Anker J, et al. More codeine fatalities after tonsillectomy in North American children. Pediatrics. 2012;129(5):e1343\u2013e1347 92."},{"issue":"11","key":"JPPT-25-00157-b16","series-title":"Laryngoscope","first-page":"1824","article-title":"Acetaminophen versus acetaminophen with codeine after pediatric tonsillectomy","volume":"110","author":"Moir","year":"2000","unstructured":"Moir MS, Bair E, Shinnick P, Messner A. Acetaminophen versus acetaminophen with codeine after pediatric tonsillectomy. Laryngoscope. 2000;110(11):1824\u20131827."},{"key":"JPPT-25-00157-b17","series-title":"J Pain Res","first-page":"105","article-title":"Acute pain management in children","volume":"3","author":"Verghese","year":"2010","unstructured":"Verghese ST, Hannallah RS. Acute pain management in children. J Pain Res. 2010;3:105\u2013123."},{"key":"JPPT-25-00157-b18","article-title":"Lexi-Drugs. Lexicomp","unstructured":"Pediatric and Neonatal. Lexi-Drugs. Lexicomp. Hudson, OH: Wolters Kluwer Health, Inc. Accessed September 29, 2025. http:\/\/online.lexi.com"},{"key":"JPPT-25-00157-b19","article-title":"FDA restricts use of prescription codeine pain and cough medicine and tramadol pain medicines in children; recommends against use in breastfeeding women","unstructured":"FDA Drug Safety Communication. FDA restricts use of prescription codeine pain and cough medicine and tramadol pain medicines in children; recommends against use in breastfeeding women. Accessed September 29, 2025. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm549679.htm"},{"issue":"4","key":"JPPT-25-00157-b20","series-title":"J Pediatr Pharmacol Ther","first-page":"422","article-title":"Pediatric Pharmacy Association 2025 KIDs list of key potentially inappropriate drugs in pediatrics","volume":"30","author":"McPherson","year":"2025","unstructured":"McPherson C, Meyers RS, Thackray J, et al. Pediatric Pharmacy Association 2025 KIDs list of key potentially inappropriate drugs in pediatrics. J Pediatr Pharmacol Ther. 2025 Aug;30(4):422\u2013439."},{"key":"JPPT-25-00157-b21","article-title":"FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder","unstructured":"US Food and Drug Administration. FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder. Accessed September 29, 2025. https:\/\/www.fda.gov\/drugs\/fdadrug-safety-podcasts\/fda-recommends-health-care-professionalsdiscuss-naloxone-all-patients-when-prescribing-opioid-pain#:: text=For%20all%20patients%20who%20are,benzodiazepines% 20or%20other%20medicines%20that"},{"issue":"7","key":"JPPT-25-00157-b22","series-title":"JAMA Health Forum","first-page":"e241920","article-title":"Naloxone availability and cost after transition to an over-the-counter product","volume":"5","author":"Marley","year":"2024","unstructured":"Marley GT, Annis IE, Egan KL, et al. Naloxone availability and cost after transition to an over-the-counter product. JAMA Health Forum. 2024;5(7):e241920."},{"key":"JPPT-25-00157-b23","article-title":"US Food and Drug Administration","unstructured":"Narcan nasal spray [package Insert]. US Food and Drug Administration. Revised August 2020. Accessed September 29, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208411Orig1s004lbl.pdf"},{"issue":"4","key":"JPPT-25-00157-b24","series-title":"J Pediatr Pharmacol Ther","first-page":"297","article-title":"Examining the critical need for tailored adolescent opioid education: a national study","volume":"28","author":"Abraham","year":"2023","unstructured":"Abraham O, Szela L, Rosenberger C, et al. Examining the critical need for tailored adolescent opioid education: a national study. J Pediatr Pharmacol Ther  2023;28(4):297\u2013307."},{"key":"JPPT-25-00157-b25","article-title":"6 ways to keep kids safe around medications","author":"Edmundson","year":"2022","unstructured":"Edmundson E, Sullivant SA. 6 ways to keep kids safe around medications. 2022. Accessed September 29, 2025. https:\/\/www.childrensmercy.org\/parent-ish\/2022\/04\/medication-safety\/"},{"key":"JPPT-25-00157-b26","article-title":"Safe storage and disposal","unstructured":"Michigan Opioid Prescribing Enrichment Network. Safe storage and disposal. Accessed September 29, 2025. https:\/\/michigan-open.org\/initiatives\/safe-storage-and-disposal\/"},{"key":"JPPT-25-00157-b27","article-title":"Disposal of unused medicines: what you should know","year":"2020","unstructured":"Food and Drug Administration. Disposal of unused medicines: what you should know. 2020. Accessed September 29, 2025. https:\/\/www.fda.gov\/Drugs\/ResourcesForYou\/Consumers\/BuyingUsingMedicineSafely\/EnsuringSafeUseofMedicine\/SafeDisposalofMedicines\/ucm186187.htm"},{"issue":"18","key":"JPPT-25-00157-b28","series-title":"Am J Health-Syst Pharm","first-page":"1539","article-title":"The opioid abuse and misuse epidemic: implications for pharmacists in hospitals and health systems","volume":"71","author":"Cobaugh","year":"2014","unstructured":"Cobaugh DJ, Gainor C, Gaston CL, et al. The opioid abuse and misuse epidemic: implications for pharmacists in hospitals and health systems. Am J Health-Syst Pharm. 2014;71(18):1539\u20131554."},{"key":"JPPT-25-00157-b29","article-title":"Prescription Drug Monitoring Programs (PDMPs)","unstructured":"Centers for Disease Control and Prevention. Prescription Drug Monitoring Programs (PDMPs). Accessed September 29, 2025. https:\/\/www.cdc.gov\/overdose-prevention\/hcp\/clinical-guidance\/prescription-drug-monitoring-programs.html"},{"issue":"3","key":"JPPT-25-00157-b30","series-title":"Ann Intern Med","first-page":"198","article-title":"Prescription drug abuse: executive summary of a policy position paper from the American College of Physicians","volume":"160","author":"Kirschner","year":"2014","unstructured":"Kirschner N, Ginsburg J, Sulmasy LS ; for the Health and Public Policy Committee of the American College of Physicians. Prescription drug abuse: executive summary of a policy position paper from the American College of Physicians. Ann Intern Med. 2014;160(3):198\u2013200."},{"key":"JPPT-25-00157-b31","article-title":"Implementation of the STEP law: voluntary non-opioid directive form","unstructured":"Implementation of the STEP law: voluntary non-opioid directive form. Accessed September 29, 2025. https:\/\/www.mass.gov\/doc\/circular-letter-dhcq-17-1-668-implementation-of-the-step-law-voluntary-non-opioid-directive-0\/download#:\u223c:text=The%20STEP%20Act%20sets%20out,MONICA%20BHAREL%2C%20MD%2C%20MPH"},{"key":"JPPT-25-00157-b32","series-title":"Subst Abuse Rehabil","first-page":"127","article-title":"The role of the pharmacist in combating the opioid crisis: an update","volume":"13","author":"Kosobuski","year":"2022","unstructured":"Kosobuski L, O\u2019Donnell C, Koh-Knox Sharp CP, et al. The role of the pharmacist in combating the opioid crisis: an update. Subst Abuse Rehabil. 2022;13:127\u2013138."},{"key":"JPPT-25-00157-b33","article-title":"Overdose prevention and response toolkit. 2024","unstructured":"Substance Abuse and Mental Health Services Administration. Overdose prevention and response toolkit. 2024. Accessed September 29, 2025. https:\/\/store.samhsa.gov\/sites\/default\/files\/overdose-prevention-response-kit-pep23-03-00-001.pdf"},{"key":"JPPT-25-00157-b34","series-title":"Preventing drug use among children and adolescents: a research-based guide for parents, educators, and community leaders","year":"2003","unstructured":"National Institute of Drug Abuse. Preventing drug use among children and adolescents: a research-based guide for parents, educators, and community leaders , 2nd edition. 2003. Accessed September 29, 2025. https:\/\/archives.nida.nih.gov\/sites\/default\/files\/preventingdruguseamongchildren.pdf"},{"key":"JPPT-25-00157-b35","article-title":"Facing addiction in America: The Surgeon General's spotlight on opioids","year":"2018","unstructured":"Substance Abuse and Mental Health Services Administration (US), Office of the Surgeon General (US). Facing addiction in America: The Surgeon General's spotlight on opioids. 2018. Accessed September 29, 2025. https:\/\/www.hhs.gov\/sites\/default\/files\/OC_SpotlightOnOpioids.pdf"},{"issue":"9","key":"JPPT-25-00157-b36","series-title":"Hosp Pediatr","first-page":"1","article-title":"Toward better pain management: the development of a \u201cPain Stewardship Program\u201d in a tertiary children\u2019s hospital","volume":"6","author":"Brenn","year":"2016","unstructured":"Brenn BG, Choudhry DK, Sacks K, et al. Toward better pain management: the development of a \u201cPain Stewardship Program\u201d in a tertiary children\u2019s hospital. Hosp Pediatr.  2016;6(9):1\u20139."},{"issue":"6","key":"JPPT-25-00157-b37","series-title":"Pediatrics","first-page":"e2020039743","article-title":"Improving opioid stewardship in pediatric emergency medicine","volume":"148","author":"Lavingia","year":"2021","unstructured":"Lavingia R, Mondragon E, McFarlane-Johansson N, Shenoi RP. Improving opioid stewardship in pediatric emergency medicine. Pediatrics. 2021;148(6):e2020039743."},{"issue":"3","key":"JPPT-25-00157-b38","series-title":"J Pediatr Surgery","first-page":"573","article-title":"Opioid stewardship in pediatric surgery: approaching zero","volume":"56","author":"Calderon","year":"2021","unstructured":"Calderon T, Hedges E, Livingston MH, et al. Opioid stewardship in pediatric surgery: approaching zero. J Pediatr Surgery. 2021;56(3):573\u2013579."},{"issue":"1","key":"JPPT-25-00157-b39","series-title":"Pediatrics","first-page":"e20161211","article-title":"Substance use screening, brief intervention, and referral to treatment","volume":"138","author":"Levy","year":"2016","unstructured":"Levy SJ, Williams JF ; for the Committee on Substance Use and Prevention. Substance use screening, brief intervention, and referral to treatment. Pediatrics. 2016;138(1):e20161211."},{"issue":"10","key":"JPPT-25-00157-b40","series-title":"J Pain","first-page":"1208","article-title":"Motives for medical misuse of prescription opioids among adolescents","volume":"14","author":"McCabe","year":"2013","unstructured":"McCabe SE, West BT, Boyd CJ. Motives for medical misuse of prescription opioids among adolescents. J Pain. 2013;14(10):1208\u20131216."},{"issue":"3","key":"JPPT-25-00157-b41","series-title":"Pediatrics","first-page":"e20161893","article-title":"Medication-assisted treatment of adolescents with opioid use disorders","volume":"138","year":"2016","unstructured":"AAP Committee on Substance Use and Prevention. Medication-assisted treatment of adolescents with opioid use disorders. Pediatrics.  2016;138(3):e20161893."},{"issue":"8","key":"JPPT-25-00157-b42","series-title":"JAMA Pediatr","first-page":"747","article-title":"Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescent and young adults, 2001-2014","volume":"171","author":"Hadland","year":"2017","unstructured":"Hadland SE, Wharam JF, Schuster MA, et al. Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescent and young adults, 2001-2014. JAMA Pediatr. 2017;171(8):747\u2013755."},{"issue":"4","key":"JPPT-25-00157-b43","series-title":"Anesth Analg","first-page":"953","article-title":"The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study","volume":"100","author":"Maxwell","year":"2005","unstructured":"Maxwell LG, Kaufmann SC, Bitzer S, et al. The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study. Anesth Analg. 2005;100(4):953\u2013958."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/31\/4\/article-p560.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/31\/4\/article-p560.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/31\/4\/article-p560.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:26:28Z","timestamp":1786364788000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/31\/4\/article-p560.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":43,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.5863\/jppt-25-00157","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}